Last ¥1,345 JPY
Change Today +4.00 / 0.30%
Volume 1.1M
As of 2:00 AM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

kyowa hakko kirin co ltd (4151) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/31/14 - ¥1,510
52 Week Low
10/8/13 - ¥985.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KYOWA HAKKO KIRIN CO LTD (4151)

Related News

No related news articles were found.

kyowa hakko kirin co ltd (4151) Related Businessweek News

No Related Businessweek News Found

kyowa hakko kirin co ltd (4151) Details

Kyowa Hakko Kirin Co., Ltd. manufactures and markets pharmaceuticals and bio-chemicals primarily in Asia, Europe, and the United States. The company’s Pharmaceuticals segment researches, develops, produces, and sells ethical drugs for the treatment of various diseases, including renal anemia, oncology, allergies, and hypertension. Its principal ethical drugs include NESP/ESPO, an ESA formulation; REGPARA, a secondary hyperparathyroidism; CONIEL, a hypertension and angina pectoris; ONGLYZA, a treatment for type 2 diabetes; GRAN, a G-CSF agent; Fentos, a transdermal product; POTELIGEO, an adult T-cell leukemia-lymphoma; Romiplate, a chronic idiopathic thrombocytopenic purpur; ALLELOCK, an antiallergic agent; Patanol antiallergic eye drops; ASACOL, an ulcerative colitis treatment; NOURIAST, an antiparkinsonian agent; and DEPAKENE, an antiepileptic agent. This segment also offers in vitro diagnostic reagents, such as POTELIGEO tests and Determiner clinical chemistry diagnostic reagents. The company’s Bio-chemicals segment produces and sells amino acids, nucleotides, and related compounds for use in pharmaceuticals and their intermediates, health foods, dietary supplements, and cosmetics. This segment also produces plant growth regulators; designs and installs plant facilities and equipment; manufactures active pharmaceutical ingredients, pharmaceutical intermediates, industrial raw materials, and health care products; sale of fine chemicals; and is involved in mail-order sale of healthcare products in Japan. In addition, the company is engaged in pharmaceuticals licensing, as well as insurance, wholesale, and retail activities. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

7,152 Employees
Last Reported Date: 03/14/14
Founded in 1949

kyowa hakko kirin co ltd (4151) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyowa hakko kirin co ltd (4151) Key Developments

Pfizer and Kyowa Hakko Kirin to Collaborate on Immuno-Oncology Combination Study

Pfizer Inc. and Kyowa Hakko Kirin announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab, which suppresses some of the immune cells that shield the tumor from the immune system, in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with solid tumors. Under the terms of the agreement, Pfizer and Kyowa Hakko Kirin will co-fund the clinical study, which will be conducted by Pfizer. This study is expected to establish a recommended dose regimen and assess the safety and preliminary efficacy of the combination. This study is expected to begin in 2015 and the results will determine the future clinical development of the combination.

Kyowa Hakko Kirin Co., Ltd. Receives Approval for Sustained-Duration G-CSF Product G-Lasta® in Japan

Kyowa Hakko Kirin Co., Ltd. announced that it has received approval for sustained-duration G-CSF product G-Lasta®subcutaneous injection 3.6mg (G-Lasta®) by the Ministry of Health, Labour and Welfare (MHLW). G-Lasta® is a sustained duration form of Granulocyte Colony-Stimulating Factor (G-CSF) product, which is produced by PEGylation of filgrastim, for treatment of chemotherapy-induced neutropenia. While filgrastim requires repeated daily doses over several days, G-Lasta® shows comparable efficacy with a single dose per chemotherapy cycle. G-Lasta® is therefore expected to reduce the burden of drug administration and to decrease frequent hospital visits of outpatients undergoing chemotherapy. Also, prophylactic administration of G-Lasta® prior to neutropenia is expected to reduce risks of infection, which results in clinical benefits such as improving the compliance with doses and schedules of chemotherapy.

Kyowa Hakko Kirin Co., Ltd. Announces Results from Phase I/II X-linked Hypophosphatemia Study

Kyowa Hakko Kirin Co., Ltd. has announced results from a long-term Phase I/II study of the investigational anti-FGF23 monoclonal antibody KRN23 in adult patients with X-linked hypophosphatemia, or XLH. The phase I/II extension study (KRN23-INT-002) was designed to evaluate long-term safety and efficacy following an initial 4-month dose escalation study (KRN23-INT-001) that was conducted in the U.S and Canada. During the extension study (KRN23-INT-002), 22 adult patients with XLH were evaluated for additional 12-months. Patients received subcutaneous injections of KRN23 every 28 days at a dose range of 0.1 to 1 mg/kg. Data from the KRN23 INT-002 study demonstrated that the increases in serum phosphorus levels, urinary phosphorous reabsorption, and 1,25 dihydroxy vitamin D3 levels observed in the initial KRN23 INT-001 study were generally sustained during the 12-month extension. All of the patients continued to demonstrate improvement in serum phosphorus levels. The majority of patients had serum phosphorus levels in the normal range (2.5 to 4.5mg/dL) at peak time by Day 7 or Day 14 for each dosing interval over the 12-month period. Additionally, the mean increases in markers of bone remodeling (procollagen type I N propeptide (P1NP) and osteocalcin) observed in KRN23 INT-001 were generally sustained in the extension study. KRN23 was well tolerated over the long-term treatment period. The most common treatment-related adverse events were injection site reaction, diarrhea, arthralgia, injection site erythema, restless legs syndrome, injection site pain, upper abdominal pain, headache, and decreased neutrophil count. Serious adverse events were reported in three subjects but were unrelated to KRN23. One patient discontinued treatment due to nephrolithiasis and one patient discontinued due to restless legs syndrome. There were no significant changes in parathyroid hormone or renal ultrasound. Serum calcium levels did not change significantly, and mild hypercalcemia was observed intermittently in two subjects.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4151:JP ¥1,345.00 JPY +4.00

4151 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albemarle Corp $58.90 USD -1.13
Genmab A/S kr250.00 DKK -2.00
MorphoSys AG €77.61 EUR +1.09
Nabaltec AG €10.64 EUR +0.015
Seattle Genetics Inc $37.18 USD -1.21
View Industry Companies

Industry Analysis


Industry Average

Valuation 4151 Industry Range
Price/Earnings 31.5x
Price/Sales 2.0x
Price/Book 1.1x
Price/Cash Flow 17.5x
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYOWA HAKKO KIRIN CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at